An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one GHB drug in a first pulse release which releases in less than about 3 hours; (b) at least one GHB drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent; and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one GHB drug in the stomach for at least about 3 hours.

Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.

Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.

The present invention is directed to compositions including probiotic bacteria in the form of biofilm, wherein the biofilm includes at least two bacterial species. Further provided are a method of using the composition of the invention, and a method of making same.

The present document describes methods of treating or preventing a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of artesunate or pharmaceutically acceptable salts thereof, and stereoisomers thereof to said subject. More particularly, the present document describes methods of treating or preventing a viral infection in a subject in need thereof comprising administering a therapeutically effective amount of a delayed release dosage form comprising an artesunate or pharmaceutically acceptable salts thereof, in combination with a carbonate salt, an artesunate emulsion having a pH value of from about 7.5 to 8.0 and comprising an artesunate or pharmaceutically acceptable salts thereof, and stereoisomers thereof stabilized with an emulsifying polymer and a soluble polymers, or a combination thereof, to the subject.

The present invention provides an impregnated porous carrier material comprising at least one active pharmaceutical ingredient (API) impregnated throughout the internal surface of a porous carrier. The present invention further provides immediate release and sustained release pharmaceutical dosage forms comprising the impregnated porous carrier material disclosed herein such that any single active pharmaceutical ingredient (API) content variability in the finished drug product has a relative standard deviation of less than 3%.

The present invention relates to a combination of phytoactives comprising plant extracts that deliver curcumin, chlorogenic acid and/or catechin. The invention also relates to a process for preparing such combination with enhanced therapeutic and pharmacological effect. The phytoactives combination is used for enhancing endurance and stamina, for significantly reducing cortisol levels thus reducing stress, for elevating hydrolysis of adenosine triphosphate (ATP), for improving blood flow, for quick recovery from sports injury, for better weight and fat loss compared to individual actives, for increasing and strengthening muscles and for increasing maximum oxygen uptake during incremental exercise.

The present invention relates to a novel use of a peptide derived from H-REV107 and, more particularly, to a composition for preventing ameliorating or treating cancer and an anticancer adjuvant composition comprising the peptide. The peptide derived from H-REV107 according to the present invention not only forms a complex with mutant KRAS, but also has an effect of inhibiting cancer through blocking an activity of RAS, and thus can be used in various ways in the fields of cancer prevention and treatment.

Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles.